Professor, Pediatrics, Ohio State University College of Medicine

Neurology

Kevin Flanigan practices Neurology. He attended Rush Medical College. Kevin M. Flanigan, DDS is a published physician. He published 43 publications, including: 'Dp412e: a novel human embryonic dystrophin isoform induced by BMP4 in early differentiated cells.'

Publications

---

• The first exon duplication mouse model of Duchenne muscular dystrophy: A tool for therapeutic development.
• Reliability and validity of ACTIVE-seated: An outcome in dystrophinopathy.
• Sanfilippo syndrome registry project and natural history studies: an example of patients, parents and researchers collaborating for a cure.
• Visual Diagnosis: Chest Pain in a Boy With Duchenne Muscular Dystrophy and Cardiomyopathy.
• A Phase I/IIa Follistatin Gene Therapy Trial for Becker Muscular Dystrophy.
• Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice.
• Outcome reliability in non-Ambulatory Boys/Men with duchenne muscular dystrophy.
• Ataluren treatment of patients with nonsense mutation dystrophinopathy.
• Duchenne and Becker Muscular Dystrophies.
• One Year Outcome of Boys With Duchenne Muscular Dystrophy Using the Bayley-III Scales of Infant and Toddler Development.
• Cryptic MHC class I-binding peptides are revealed by aminoglycoside-induced stop codon read-through into the 3' UTR.
• Feasibility and Safety of Systemic rAAV9-hNAGLU Delivery for Treating Mucopolysaccharidosis IIIB: Toxicology, Biodistribution, and Immunological Assessments in Primates.
• Dystrophin as a therapeutic biomarker: Are we ignoring data from the past?
• Feasibility and Safety of Systemic rAAV9-hNAGLU Delivery for Treating MPS IIIB: Toxicology, Bio-distribution and Immunological Assessments in Primates.
• Dexmedetomidine and ketamine sedation for muscle biopsies in patients with Duchenne muscular dystrophy.
• A comparative study of N-glycolylneuraminic acid (Neu5Gc) and cytotoxic T cell (CT) carbohydrate expression in normal and dystrophin-deficient dog and human skeletal m...
• Exome sequencing identifies a DNAJB6 mutation in a family with dominantly-inherited limb-girdle muscular dystrophy.
• The 2-min walk test is sufficient for evaluating walking abilities in sporadic inclusion body myositis.
• The ZZ Domain of Dystrophin in DMD: Making Sense of Missense Mutations.
• Recurrent central nervous system white matter changes in charcot-marie-tooth type X.
• Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial.
• Anti-dystrophin T cell responses in duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect.
• Position of glycine substitutions in the triple helix of COL6A1, COL6A2, and COL6A3 is correlated with severity and mode of inheritance in collagen VI myopathies.
• Eteplirsen for the treatment of duchenne muscular dystrophy.
• Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network.
• Correlation of knee strength to functional outcomes in becker muscular dystrophy.
• Proof of concept of the ability of the kinect to quantify upper extremity function in dystrophinopathy.
• Precordial R Wave Height Does Not Correlate with Echocardiographic Findings in Boys with Duchenne Muscular Dystrophy.
• LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy.
• Cardiac management in neuromuscular diseases.
• Camptocormia as a late presentation in a manifesting carrier of duchenne muscular dystrophy.
• A practical approach to molecular diagnostic testing in neuromuscular diseases.
• RNA Interference Inhibits DUX4-induced Muscle Toxicity In Vivo: Implications for a Targeted FSHD Therapy.
• Effects of Angiotensin-Converting Enzyme Inhibitors and/or Beta Blockers on the Cardiomyopathy in Duchenne Muscular Dystrophy.
• Evidence-based path to newborn screening for duchenne muscular dystrophy.
• A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy.
• Abnormal expression of mu-crystallin in facioscapulohumeral muscular dystrophy.
• Sarcolemmal reorganization in facioscapulohumeral muscular dystrophy.
• Dp412e: a novel human embryonic dystrophin isoform induced by BMP4 in early differentiated cells.
• A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy.
• Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation duchenne muscular dystrophy.
• Identification of new dystroglycan complexes in skeletal muscle.

Doctors Specialties

---

• Dentistry
• Neurology

Accepted Insurances

---

• Delta Dental Premier
• Encompass

Education

---

• Johns Hopkins University
• University of Michigan Hospitals and Health Centers
• Rush Medical College

Hospital

---

• Nationwide Children's Hospital

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Steven G. Simensky, MD This Doctor is OpenDoctor Recommended.
	Dr. Eskender Getachew, MD This Doctor is OpenDoctor Recommended.
	Dr. John G. Oas, MD This Doctor is OpenDoctor Recommended.
	Dr. Gregory M. Figg, MD This Doctor is OpenDoctor Recommended.
	Dr. Yasushi Kisanuki, MD This Doctor is OpenDoctor Recommended.
	Dr. Erin M. Canale, MD
	Dr. Aaron T. Barkley, DDS
	Dr. Ronald L. Clowson, DDS
	Dr. Richard A. Carstens, DDS
	Dr. Anu Garg, DMD
	Dr. Gregory P. Haworth, DDS
	Dr. Phillip J. Paul, DDS

---

Doctor Directory | TOS | twitter | FB | Angel | blog